Official PDF Translation•Chinese Journal of New Drugs

Efficacy and Safety of Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

Authors: Y. Zhang; L. Wang; H. Li; J. Chen; X. Liu

DOI: 10.1007/s12345-024-01234-5Status: Verified Translated Edition

Sponsored AdvertisementAd Placement Area

reCAPTCHA Bot Shield Active

Preparing Secure Academic Download

Verifying human reader & generating high-resolution document...

Verifying Document Integrity15s remaining

← Back to Article

Protected by Google reCAPTCHA v3.•Privacy•Terms

Sponsored ContentAdSense In-Feed Ad Slot

Key Findings in This Report

• TAS-102 significantly improves overall survival and progression-free survival in metastatic colorectal cancer patients who have failed prior therapies. • The objective response rate is low (1.6%), but disease control rate is 44%, indicating clinical benefit in a subset of patients. • Common grade 3/4 adverse events include neutropenia, leukopenia, and anemia, which are manageable with dose modifications and supportive care. • TAS-102 is a valuable treatment option in the third-line setting and beyond, with a favorable risk-benefit profile.